Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Master Protocol for a Phase I/II Open-label Safety and Efficacy Study of LNP.UCD.ABE, a Lipid Nanoparticle-delivered Base Editing Therapy, in Patients With Urea Cycle Disorders Due to Variants Amenable to Corrective Editing by LNP.UCD.ABE

NCT07667387 is registered in ClinicalTrials.gov with Rebecca Ahrens-Nicklas as lead sponsor.

NCT NCT07667387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07667387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Master Protocol for a Phase I/II Open-label Safety and Efficacy Study of LNP.UCD.ABE, a Lipid Nanoparticle-delivered Base Editing Therapy, in Patients With Urea Cycle Disorders Due to Variants Amenable to Corrective Editing by LNP.UCD.ABE
Lead sponsor
Rebecca Ahrens-Nicklas
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 7, 2026
Completion date
September 30, 2028
Enrollment
7 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carbamoyl-phosphate synthase i deficiency, urea cycle disorders